Multifocal Electrophysiologic Findings After Intravitreal... | NCT00417833

Studies
Multifocal Electrophysiologic Findings After Intravitreal Bevacizumab(Avastin)Treatment

NCT00417833

Sponsor

Asociación para Evitar la Ceguera en México

Status

Terminated

Last Update Posted

Jun 3, 2024Actual

Enrollment

Not provided

Phase

Phase 2Phase 3

Conditions

Diabetic Proliferative Retinopathy
Vascular Vein Oclussion
Choroidal Neovascularization

Interventions

Intravitreal Bevacizumab

Countries

Not provided

Protocol Section

Identification Module Status Module Sponsor/Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms/Interventions Module Outcomes Module Eligibility Module Contacts/Locations Module References Module IPD Sharing Statement Module

Results Section

Participant Flow Module Baseline Characteristics Module Outcome Measures Module Adverse Events Module More Info Module

Annotation Section

Annotation Module

Document Section

Large Document Module

Derived Section

Miscellaneous Info Module Condition Browse Module Intervention Browse Module

Protocol Section

Identification Module

NCT ID

Results Section

No data available

No data is available for this block.

Annotation Section

No data available

No data is available for this block.

Document Section

No data available

No data is available for this block.

Derived Section

Miscellaneous Info Module

Version Holder

Status Module

Record Verification Date

May 2024

Overall Recruitment Status or Expanded Access Status

Terminated

Last Known Status

Not provided

Delayed Posting

Not provided

Why Stopped

Poor accrual

Expanded Access Info

Start Date

Dec 2005

Primary Completion Date

Not provided

Completion Date

Jul 2006

First Submitted Date

Jan 3, 2007

First Submission Date that Met QC Criteria

Jan 3, 2007

First Posted Date

Jan 4, 2007Estimated

Results Waived

Not provided

Results First Submitted Date

Not provided

Results First Submitted that Met QC Criteria

Not provided

Results First Posted Date

Not provided

Certification/Extension (aka Delayed Results) First Submitted Date

Not provided

Certification/Extension First Submitted that Passed QC Review

Not provided

Certification/Extension First Posted Date

Not provided

Last Update Submitted Date

May 31, 2024

Last Update Posted Date

Jun 3, 2024Actual

Description Module

Brief Summary

Purpose: Determine the short-term safety of intravitreal bevacizumab by multifocal electroretinography (mf-ERG).

Methods: 120 eyes with choroidal neovascularization, proliferative diabetic retinopathy and retinal vein occlusion received intravitreal bevacizumab (2.5mg/0.1cc). All patients underwent best corrected visual acuity, fluorescein angiography, optical coherent tomography and mf-ERG before and 1 month after treatment.

Detailed Description

Not provided

Design Module

Study Type

Interventional

Number of References to an Expanded Access Study

Not provided

Expanded Access Types

Not provided

Patient Registry

Not provided

Target Follow-Up Duration

Not provided

Phases

Phase 2Phase 3

Interventional Study Design

Allocation

Biospecimen

No data available

No data is available for this block.

Enrollment

Not provided

Name	Type	Description	Arm Group Labels	Other Names
Intravitreal Bevacizumab	Drug

Eligibility Module

Eligibility Criteria

Inclusion Criteria:

Proliferative diabetic retinopathy, vascular vein oclussion, choroidal neovascularization
Multifocal electroretinogram before intravitreal bevacizumab and at 1,3, and 6 months after treatment
Completely studies

Exclusion Criteria:

Complications

Tractional Detachment
Endophthalmitis

Accepts Healthy Volunteers

Not provided

Sex

All

Sex/Gender Based

Not provided

Sex/Gender Description

Not provided

Minimum Age

Not provided

Maximum Age

Not provided

Standard Ages

ChildAdultOlder Adult

Study Population

Not provided

Sampling Method

Not provided

Contacts/Locations Module

Central Contacts

Not provided

Overall Officials

Name	Affiliation	Role
Myrian L Hernández, MD	Asociación para Evitar la Ceguera en México	Principal Investigator

Locations

Not provided

Condition Browse Module

MeSH Terms

ID	Term
D020256	Choroidal Neovascularization

Ancestor Terms

ID	Term
D015862	Choroid Diseases
D014603	Uveal Diseases
D005128	Eye Diseases
D009389	Neovascularization, Pathologic

Browse Leaves

Not provided

Browse Branches

Not provided